Natick biotech receives $30M in funding from Hong Kong firm

Natick cancer treatment company Affylmmune Therapeutics, Inc. announced Thursday it has closed a $30-million Series A+ funding by ORI Capital Limited to advance a cancer treatment study.

The funding will advance the Phase 1 study of AIC1000, a treatment for anaplastic thyroid cancer. 

AffyImmune plans to double its headcount over the next nine months with a focus on expanding its leadership teams, said the announcement.

As part of the investment, ORI Capital’s director, Elaine Yang, will join AffyImmune’s board of directors.

ORI Capital is a healthcare fund manager based in Hong Kong.